Research information only, not medical advice. The dose studied in the trials that led to approval — and the approved dose of tesamorelin (Egrifta) — is 2 mg by subcutaneous injection once daily, for HIV-associated lipodystrophy. Uses outside that indication are off-label and not FDA-approved.
Tesamorelin is FDA-approved for one indication — reducing excess visceral abdominal fat in HIV-associated lipodystrophy — at 2 mg subcutaneously once daily, the dose used across the randomised trials that support it (Badran et al., 2025). No dose is established for the off-label body-composition uses it is also marketed for. This page reports the studied and approved dose, not a protocol to follow.
For the full evidence base, clinical trials, and regulatory status, see the Tesamorelin research overview . Related: tesamorelin side effects , tesamorelin before and after .
Sources
Frequently asked questions
- What is the approved dose of tesamorelin?
- 2 mg by subcutaneous injection once daily, for HIV-associated lipodystrophy — the only FDA-approved indication. Other uses are off-label with no established dose.
- Is there a tesamorelin dose for bodybuilding?
- No. Tesamorelin is only approved for HIV-associated lipodystrophy; body-composition use in healthy adults is off-label and not FDA-approved, with no established dose.
Updated · sourced to primary documents